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ABSTRACT
Introduction: This retrospective cohort study 
compared the direct medical costs of successful 
versus unsuccessful catheter ablation in Medicare-
aged patients with atrial fibrillation (AF), using 
medical claims data. Methods: AF patients with 
≥12 months of continuous medical/pharmacy 
coverage pre- and postablation were identified 
from the MarketScan® Medicare database 
(January 2003 to December 2006). For study 
inclusion, patients were required to have ≥2 AF 
inpatient/outpatient visits within 6 months and 
to have received antiarrhythmic drug therapy 
within 12 months prior to the index ablation. 




of antiarrhythmic drug therapy 6-12 months 
postablation. Results: Of 135 patients identified 
(67% men, mean age 73 years), ablation was 
successful in 69 (51.1%); most patients (96%) 
underwent a single procedure. Patients with 
successful ablation discontinued antiarrhythmic 
drug treatment after (mean) 54 days. Use of 
rate-control and anticoagulant drugs decreased 
after successful ablation, from 87% to 67% 
and from 86% to 64% of patients, respectively. 
Among failed ablation patients, 74% versus 70% 
received rate-control drugs, and 88% versus 82% 
received anticoagulants pre- versus postablation. 
Mean ± SD per-patient procedural costs were 
$13,655±$12,761 for successful compared with 
$17,294±$26,502 (P=0.21) for failed ablation, 
while AF-related medical costs over 12 months 
postablation were $2394±$642 and $2703±$1706, 
respectively (P<0.001). Overall costs tended to be 
lower for successful ($16,049±$12,536) than for 
failed ($19,997±$13,958) AF ablation (P=0.07). 
These findings are subject to the limitations 
imposed by a retrospective database analysis 
and a small sample size. Conclusion: Outside 
the clinical-trial setting, catheter ablation for 
second-line treatment of AF proved unsuccessful 
in half of Medicare-aged patients. Direct medical 
costs did not differ significantly between 
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patients with failed and successful ablations. 
The high rate and costs of AF ablation failure in 
the Medicare-aged population reinforce the need 
for better understanding of prognostic factors for 
ablation outcome.
Keywords: arrhythmia; atrial fibrillation; 
catheter ablation; cohort study; costs; 
elderly; Medicare
INTRODUCTION
Atrial fibrillation (AF) is the most frequently 
encountered arrhythmia in clinical practice, 
affecting an estimated 3 million adults in the 
US.1 The condition is predominantly a disease 
of the elderly, increasing in prevalence from 
~0.1% in the adult population under 55 years 
of age to 6% in those over 65 years and to 
8%-10% in those over 80 years.2,3 Accordingly, 
the burden of AF is borne overwhelmingly 
by the Medicare-aged population, with an 
estimated 82% of cases occurring in the 65- to 
85-year age group.3 AF is an established risk 
factor for cerebral thromboembolism and heart 
failure,4,5 and hospitalization and mortality 
rates for AF have risen significantly in recent 
decades.6-8 Consequently, the economic impact 
of AF is substantial, amounting to an estimated 
$6-$7 billion per annum in direct medical 
expenditure in the US, with the primary cost 
driver being hospitalization.9,10
Clinical management of AF has three 
principal objectives—control of ventricular rate, 
maintenance of sinus rhythm, and prevention 
of thromboembolism.11 In view of the potential 
toxicity and limited efficacy of current Class I 
and III antiarrhythmic drugs, nonpharmacologic 
techniques are increasingly being applied for 
rhythm control in AF. Radiofrequency catheter 
ablation of AF has evolved rapidly over the past 
decade and is now a routine procedure in most 
major medical centers.12,13 In selected patient 
populations, catheter ablation has demonstrated 
superiority over antiarrhythmic drug therapy 
in maintaining sinus rhythm, improving 
symptoms, and preventing hospitalization for 
AF.14 As a potentially curative procedure, catheter 
ablation offers the prospect of reducing the long-
term healthcare costs of AF by avoiding repeat 
episodes of hospitalization.15,16
In recent years, the patient population 
undergoing catheter ablation for AF has become 
progressively older, with more persistent AF 
and more advanced structural heart disease.17 
However, there is relatively little published 
literature on the clinical and economic outcomes 
of AF ablation therapy in the Medicare-aged 
population outside the controlled environment 
of clinical trials. Using a medical claims database, 
the present study was undertaken to determine 
the perceived success rate of catheter ablation in 
Medicare-aged patients with AF, and to compare 
medical costs between patients with successful 
and failed ablation procedures in the “real 
world” (ie, nonclinical-trial) setting.
MATERIALS AND METHODS
Study Design
This retrospective cohort study utilized data 
from the proprietary MedStat MarketScan® 
Medicare Supplemental and Coordination of 
Benefits database for the period between January 
2003 and June 2007. The MarketScan databases 
are derived from employer or government-funded 
(Medicare) healthcare insurance plans and 
include information on 21.6 million individuals 
of all ages covered under a variety of fee-for-
service and capitated provider reimbursement 
schemes. MarketScan has formed the basis 
of more than 250 peer-reviewed publications 
published over the last 20 years.18,19 Diagnostic 
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information was identified using International 
Classification of Diseases, Ninth Revision, Clinical 
Modification (ICD-9-CM) codes, and procedures 
were identified. In compliance with the Health 
Insurance Portability and Accountability Act of 
1996 (HIPAA), all patient data used in this study 
were de-identified and thus Institutional Review 
Board approval was not required.
Sample Selection
Men and women aged ≥19 years who were 
diagnosed with AF (ICD-9-CM code 427.31) 
in an inpatient setting between January 2004 
and January 2005, and who additionally 
underwent an intracardiac catheter ablation 
procedure for treatment of supraventricular 
tachycardia (Current Procedural Terminology 
[CPT] code 93651: intracardiac catheter ablation 
of arrhythmogenic focus; for treatment of 
supraventricular tachycardia by ablation of fast 
or slow atrioventricular pathways, accessory 
atrioventricular connections or other atrial foci, 
singly or in combination) between January 2004 
and December 2005, were identified. Patients were 
required to have undergone catheter ablation 
within 6 months of their qualifying AF diagnosis 
(the first ablation procedure was designated 
as index), and to have continuous medical/
pharmacy coverage for the 12-month period 
immediately before and after the index ablation. 
To control for catheter ablation procedures 
unrelated to AF, patients were excluded if they 
had an ICD-9-CM diagnosis code for paroxysmal 
supraventricular tachycardia (427.0) or other 
(unspecified) supraventricular tachycardias 
(427.89) within the 12-month pre-index period. 
To ensure that patients were being actively 
managed for AF, they were required to have 
had two or more office visits or hospitalizations 
for AF within the 6-month period preceding 
the index ablation. Furthermore, in line with 
current recommendations that ablation should 
be reserved for use as a second-line treatment 
option in AF,11,20 patients were required to 
have a claim submission for antiarrhythmic 
medication during the 12-month period prior 
to the index ablation.
Outcome Measures
For the purpose of this analysis, ablation 
success was defined as the absence of 
antiarrhythmic drug therapy during the period 
6-12 months postablation. In the event that a 
patient provided evidence of having undergone 
a repeat ablation procedure(s) within 6 months 
of the first (index) procedure, success rates were 
determined for the “first ablation” and “all 
ablations.” Since suppressive antiarrhythmic 
drug therapy is commonly employed in the early 
postablation phase,20 antiarrhythmic use during 
the period 0-5 months following the ablation 
procedure was not taken into consideration in 
determining ablation outcome.
In evaluating medical resource utilization, 
direct medical costs were summarized for: 
(1) hospitalizations involving the ablation 
procedure(s); (2) other inpatient/outpatient 
medical services; and (3) drug treatment over the 
12 months following the index ablation.
Statistical Analysis
Statistical analyses were conducted using 
the SAS® System version 9.1.3 (SAS Institute 
Inc., Cary, NC, USA). Categorical results were 
compared using the χ2 test for significance. To 
determine statistical differences in costs, log-
transformed direct costs were compared between 
the ablation success and failure groups using 
Student’s t-test. A probability value of P≤0.05 
was considered statistically significant. Data are 
expressed as mean ± standard deviation (SD).
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RESULTS
Study Population
Of a total of 1022 patients identified in 
the database as having undergone a catheter 
ablation procedure for AF at a specialist 
medical center during the specified study 
period, 135 patients satisfied all the study 
eligibility criteria and were included in the 
analysis (Figure 1). Baseline demographic 
characteristics and comorbidities of these 
patients are summarized in Table 1. Overall, 
the mean age of the study population was 
73±5.4 years and two-thirds of patients 
were male. A high proportion of patients 
had cardiovascular comorbidities—most 
commonly coronary artery disease (54.1%), 
hypertension (43.7%), valvular heart disease 
(34.8%), and congestive heart failure (26.7%). 
Prior to the index ablation, all patients had 
received antiarrhythmic drug therapy for 
Figure 1. Patient identification and selection. *74 of 209 patients who met the study’s data requirements underwent catheter 
ablation without satisfying currently accepted guideline recommendations for use of this procedure (ie, demonstrated 
refractoriness or intolerance to ≥1 Class Ic or III antiarrhythmic drugs). Ablation outcomes based on prescription claims 
data could not be determined for these patients. AF=atrial fibrillation; PSVT=paroxysmal supraventricular tachycardia 
(International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] diagnosis code 427.0).
AF patients with ablation
Jan 2004-Dec 2005
n=1022 Not continuously enrolled 12 months 
pre- and post-index ablation
n=399
PSVT diagnosis during
12 months prior to index ablation
n=186
<2 AF oce visits/hospitalizations 
during 6 months prior to index ablation
n=226
Did not meet data quality requirements
n=2
No antiarrhythmic therapy during 
12 months prior to index ablation 
n=74*
Continuous enrollment
12 months pre- and post-index ablation
n=623
No PSVT diagnosis during
12 months prior to index ablation
n=437
≥2 AF oce visits/hospitalizations 
during 6 months prior to index ablation
n=211
Met data quality requirements
n=209
AF ablation patients with prior 
antiarrhythmic therapy during 12 months 
prior to index ablation (analysis population)
n=135
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rhythm control, most frequently amiodarone 
(49.6%), sotalol (31.9%), dofetilide (14.1%), 
and propafenone (14.1%). Most patients 
had received drug treatment for ventricular 
rate control (80.7%), primarily beta-blockers 
(63.7% of all patients), and calcium channel 
blockers (39.3%), as well as anticoagulant 
therapy (86.7%), most commonly warfarin 
(85.9% of all patients). A small minority of 
patients had additionally received antiplatelet 
drug therapy (11.9%).
Catheter ablation was judged to have been 
successful, according to the study criterion, in 
69 patients (51.1% of the study population) 
and unsuccessful in 66 patients (48.9%). The 
two patient subgroups (“ablation success” 
group and “ablation failure” group) were 
generally well matched in terms of baseline 
demographic and clinical characteristics, 
geographic distribution, and healthcare 
provision (Table 1). Preablation use of rate-
control agents, anticoagulants, and antiplatelet 








Male, n (%) 91 (67.4) 45 (65.2) 46 (69.7) 0.58
Age, years, mean±SD 73.0±5.4 73.2±5.0 72.8±5.8 0.66
Age category, n (%)
 55-64 years 1 (0.7) 0 1 (1.5)
 65-74 years 86 (63.7) 45 (65.2) 41 (62.1)
 ≥75 years 48 (35.6) 24 (34.8) 24 (36.4)
Payer type, n (%) 0.63
 Medicare Fee for Service 121 (89.6) 61 (88.4) 60 (90.9)
 Medicare Encounter 14 (10.4) 8 (11.6) 6 (9.1)
Geographic region, n (%) 0.86
 North east 11 (8.1) 5 (7.2) 6 (9.1)
 North central 66 (48.9) 33 (47.8) 33 (50.0)
 South 36 (26.7) 18 (26.1) 18 (27.3)
 West 22 (16.3) 13 (18.8) 9 (13.6)
Comorbidities, n (%)
 Ischemic stroke 4 (3.0) 2 (2.9) 2 (3.0) 0.96
 Congestive heart failure 36 (26.7) 19 (27.5) 17 (25.8) 0.82
 Valvular heart disease 47 (34.8) 27 (39.1) 20 (30.3) 0.28
 Coronary artery disease 73 (54.1) 44 (63.8) 29 (43.9) 0.02
 Peripheral vascular disease 10 (7.4) 7 (10.1) 3 (4.5) 0.21
 Cardiomyopathy 15 (11.1) 8 (11.6) 7 (10.6) 0.86
 Pulmonary disease 35 (25.9) 22 (31.9) 13 (19.7) 0.11
 Thyroid disease 14 (10.4) 3 (4.3) 11 (16.7) 0.02
 Diabetes 21 (15.6) 15 (21.7) 6 (9.1) 0.04
 Hypertension 59 (43.7) 29 (42.0) 30 (45.5) 0.69
Charlson Comorbidity Index, mean±SD 1.5±1.6 1.8±1.8 1.3±1.4 0.09
Adv Ther (2010) 27(9):600-612. 605
drugs did not differ significantly between the 
two groups.
Ablation Procedures and Clinical Outcomes
Most patients (97% with successful ablation 
and 94% with failed ablation, as defined 
according to the study criterion) underwent only 
one ablation procedure during the study period. 
For those patients undergoing a repeat procedure 
(two patients in the “ablation success” group and 
four patients in the “ablation failure” group), this 
was performed 5.1-12.0 months after the index 
event. All ablation procedures were conducted 
in the inpatient setting, and the mean length of 
stay per procedure was 2.5±3.2 days for patients 
with successful ablation and 2.3±2.3 days for 
those with failed ablation (median 1.0 day for 
each group).
After  successful  ablat ion,  patients 
discontinued antiarrhythmic drug therapy 
within 53.6±48.1 days, compared with 
238±103 days after failed ablation (by 
definition, patients with failed ablation 
remained on antiarrhythmic drug therapy for 
at least 6 months following the procedure). Use 
of adjunctive drug therapy for AF also declined 
after successful ablation: from 87% of patients 
preablation to 67% at 6-12 months postablation 
for rate-control drugs, from 86% to 64% of 
patients for anticoagulants, and from 16% to 
4% of patients for antiplatelet drugs. In contrast, 
for patients with failed ablation the use of these 
agents did not change appreciably between the 
pre- and postablation periods: from 74% to 70% 
for rate-control drugs, and from 88% to 82% for 
anticoagulants, while 7.6% of patients received 
antiplatelet drugs both pre- and postablation. 
During the postablation period, there were no 
significant differences in individual comorbidity 
frequencies between patients with successful 
and failed ablation procedures.
Direct Medical Costs Associated with 
Ablation and AF Management
The mean cost per ablation procedure 
was $13,270±$12,139 for patients with 
s u c c e s s f u l  a b l a t i o n  c o m p a r e d  w i t h 
$16,306±$25,315 for patients with failed 
ablation (P=0.24). Similarly, the mean 
ablation cost per patient tended to be 
lower for patients with successful ablation 
($13,655±$12,761) than for those with 
failed ablation ($17,294±$26,502; P=0.21). 
In contrast, median ablation costs differed 
only marginally between the “ablation 
success” and “ablation failure” groups 
(cost per procedure: $11,930 vs. $11,643, 
respectively; cost per patient: $11,795 vs. 
$11,778, respectively). Subsequent AF-related 
medical costs (ie, costs for claims with a 
primary AF diagnosis) during the 12-month 
period following the index ablation were 
$2394±$642 for patients with successful 
ablation versus $2703±1706 for patients with 
failed ablation (P<0.001). Successful ablation 
was associated with significantly lower 
pharmacy costs ($123±$43 vs. $808±$625; 
P<0.0001) and outpatient costs ($763±$469 
vs. $1080±$657; P=0.02). On exclusion 
of pharmacy costs (a likely confounder, 
since patients with successful ablation by 
definition did not receive antiarrhythmic 
therapy), AF-related medical costs for the 
ablation success and failure groups were 
not dissimilar ($2272 vs. $1894 per patient, 
respectively; no statistical comparison 
available). Overall, the total annualized cost 
per patient of medical management of AF 
(ie, cost of ablation procedures plus other 
AF-related services) tended to be lower in 
patients with successful ablation than in 
those with failed ablation ($16,049±$12,536 
vs. $19,997±$13,958; P=0.07) (Table 2).
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Cost per patient of inpatient ablation procedures
 Mean±SD 15,434±20,656 13,655±12,760 17,294±26,502 0.21
 Median 11,795 11,795 11,778
Subsequent AF-related costs per patient*
Inpatient†
 Mean±SD 1031±6061 1361±7509 687±4063 0.57
 Median 0 0 0
Outpatient
 Mean±SD 918±1231 763±1076 1080±1364 0.02
 Median 558 469 657
Pharmacy
 Mean±SD 458±660 123±197 808±784 <0.0001
 Median 216 43 625
Laboratory
 Mean±SD 39±155 44±157 34±155 0.74
 Median 0 0 0
Emergency
 Mean±SD 11±66 11±72 10±60 0.69
 Median 0 0 0
Radiology
 Mean±SD 68±280 81±322 55±231 1.00
 Median 0 0 0
Ancillary/other
 Mean±SD 20±69 12±53 28±82 0.45
 Median 0 0 0
Total
 Mean±SD 2545±6298 2394±7677 2703±4478 <0.001
 Median 1292 642 1706
Total cost per patient 
 Mean±SD 17,979±22,294 16,049±17,135 19,997±26,635 0.07
 Median 13,518 12,536 13,958
*Includes costs for claims with a primary AF diagnosis only.
†Costs associated with the primary admission diagnosis of AF.
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DISCUSSION
Available evidence from clinical studies 
suggests that catheter-based ablation of AF offers 
benefit to selected patients who are resistant to 
pharmacologic or electrical conversion to sinus 
rhythm.11,20 Moreover, ablation therapy, either 
alone or with adjuvant antiarrhythmic drug 
therapy, appears to offer a comparable level 
of AF control in the elderly (>65 years) to that 
achieved in younger patients.21-26 However, 
these studies provide no clear indication of 
absolute rates of treatment success: ablation 
outcomes vary considerably from study to 
study because of confounding factors such as 
differences in patient populations (eg, age, 
concomitant cardiac disease, pattern and 
duration of AF, antiarrhythmic drug use), 
duration of follow-up, frequency of arrhythmia 
monitoring, and definition of ablation success, 
as well as technical aspects of the procedure 
itself.20 Few randomized, double-blind studies 
of catheter ablation have been performed, and 
cohort studies have frequently lacked clear and 
prospectively defined outcomes. The ongoing 
Catheter Ablation Versus Antiarrhythmic Drug 
Therapy for Atrial Fibrillation (CABANA) pilot 
trial (NCT00578617), a randomized, open-
label comparison of catheter ablation versus 
pharmacotherapy for rate and rhythm control in 
AF, is one of the few studies to enroll Medicare-
aged patients (up to 90 years of age).
Catheter ablation is currently recommended 
as a second-line treatment option for AF, with its 
use reserved for symptomatic patients who are 
refractory or intolerant to at least one Class I or 
Class III antiarrhythmic agent.20 However, it would 
appear that the procedure is not infrequently 
employed in clinical practice as a viable first-
line therapy for AF: in our study we excluded 
over one-third of otherwise eligible patients 
(74 out of 209) who provided no documented 
evidence of prior antiarrhythmic drug exposure. 
When catheter ablation is used in accordance 
with accepted guideline recommendations, the 
results of the study indicate that, in the “real-
world” setting (ie, outside the controlled clinical 
trial), the procedure is successful, as defined by 
the absence of antiarrhythmic drug therapy 
at 6 months postablation, in approximately 
one-half of Medicare-aged patients with AF. 
This figure is consistent with the results of a 
worldwide survey (1995-2002) of the outcomes 
of nearly 9000 catheter ablation procedures 
performed for AF in a large and heterogenous 
population (age unspecified), which reported 
an antiarrhythmic drug-free success rate 
(ie, proportion of patients asymptomatic in the 
absence of any antiarrhythmic drug) of 52.0% 
over a (median) 12-month (range, 1-98 months) 
follow-up period.27 This result was achieved 
with 27% of patients requiring a second or 
third ablation procedure, which is considerably 
higher than the corresponding figure (4%-5%) 
in our Medicare-aged population. It should be 
noted that despite careful patient selection, 
there was marked variation in ablation efficacy 
between the various electrophysiology centers 
participating in the survey, with antiarrhythmic 
drug-free success rates ranging from 15% to 
77%.27 This variation in success rate appeared 
to be independent of ablation technique and 
AF type, suggesting that other factors, such as 
the use of repeat ablation procedures, physician 
experience, and the length of patient follow-up, 
may be important determinants of the efficacy 
of catheter ablation in clinical practice.27 It is 
recognized that catheter ablation for AF is not a 
genuinely curative procedure, and that AF may 
recur long (>1 year) after completion of successful 
ablation,28-30 possibly on account of restoration 
of conduction across the lesion set.31 Long-term 
follow-up of patients who experience prolonged 
(≥1 year) AF-free periods after successful catheter 
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ablation has revealed appreciable attrition 
rates, with a 25% cumulative recurrence rate at 
5 years postablation.30
Given the constraints of the available data in 
the present study, we were unable to determine 
ablation success in terms of symptom control or 
prevention of AF recurrence. In the absence of 
arrhythmia monitoring data, we instead defined 
ablation success as freedom from the need for 
continued antiarrhythmic drug therapy at 
6 months postablation. One drawback of this 
approach is that it may potentially underestimate 
the true effectiveness of the AF ablation 
procedure, since the use of antiarrhythmic drug 
therapy postablation is not necessarily indicative 
of treatment failure. New-onset atrial tachycardias 
occur in up to 25% of patients following catheter 
ablation for AF32,33 and, although many of 
these arrhythmias are self-limiting and resolve 
spontaneously, prophylactic antiarrhythmic 
therapy is commonly administered for the 
first 1 to 3 months postablation.34 It should be 
recognized, however, that if a patient shows a 
good clinical response during this early phase, 
the physician may be reluctant to withdraw 
drug therapy to assess the clinical efficacy of the 
ablation procedure alone. This is particularly the 
case with elderly patients, who are more likely 
than their younger counterparts to remain on 
antiarrhythmic drug therapy beyond this initial 
period.26 Accordingly, some of the 66 patients 
who were receiving antiarrhythmic drug therapy 
at 6 months postablation may have undergone 
a successful ablation procedure, although the 
likelihood of achieving a completely successful 
result more than 6 months after the initial 
ablation is low. The majority of these cases 
likely represent ablation failures or attempts at 
“hybrid” therapy, with antiarrhythmic drugs 
being used in conjunction with the recent 
ablation procedure to control AF. It is well 
known that catheter ablation may be partially 
effective and allow a patient with AF, previously 
refractory to antiarrhythmic therapy, to become 
drug responsive.20 For these patients, drug 
therapy following ablation is an acceptable long-
term management strategy, and often preferable 
to repeat ablation.
Previous economic evaluations of catheter 
ablation for AF have generally involved cost-
effectiveness comparisons with medical 
therapy.35-38  A Canadian study concluded that 
catheter ablation represented a fiscally sensible 
alternative to medical therapy in AF, with ablation 
costs (~$16,000-$21,000, including costs of 
periprocedural medical care and complications) 
approximating to those of ongoing medical care 
after (mean) 4 years of follow-up.36 A more recent 
US study, using a disease-simulation Markov 
model (based on clinical trial, registry, and 
Medicare claims data) for a hypothetical cohort 
of patients with treatment-refractory paroxysmal 
AF, concluded that, over a 5-year time-frame, 
the cumulative costs of catheter ablation with/
without adjunctive antiarrhythmic drug therapy 
($25,584) would be marginally higher than those 
of ongoing medical therapy ($19,898), with cost 
neutrality being achieved after 10 years.38
The present study indicates that the direct 
medical costs of catheter ablation in Medicare-
aged patients with AF are comparable to those 
reported above, amounting to approximately 
$16,000-$20,000 (inclusive of the ablation 
procedure and other AF-related services) over 
the first 12 months postablation. Over the same 
period, an unsuccessful ablation procedure is, on 
average, approximately $4000 more expensive 
than a successful one, partly on account of the 
significantly greater expenditure devoted to 
pharmacy and outpatient services. It should 
be noted, however, that this cost differential is 
likely exaggerated by the confounding influence 
of pharmacy costs, which (not unexpectedly) 
were higher in patients with unsuccessful 
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ablation. With time, the cost differential might 
be expected to widen further if repeat ablations 
are performed following failure of the index 
ablation. As expected, the major cost component 
is represented by the ablation procedure and its 
associated hospitalization event. This composite 
cost tended to be higher for patients who 
subsequently experienced ablation failure rather 
than ablation success (mean, $16,306 vs. $13,270 
per ablation procedure), although the large SDs 
($25,315 vs. $12,139, respectively) would suggest 
that the mean costs were distorted by extreme 
outlying values, possibly as a result of procedural 
complications such as stroke, embolism, 
hemorrhage, tamponade, or pericardial drainage. 
Against this, the close similarity in median 
costs for the “ablation success” and “ablation 
failure” groups ($11,643 vs. $11,930 per ablation 
procedure, respectively) would argue against 
major differences in complication patterns 
between the two patient groups. Nevertheless, 
the relatively high proportion of ablation 
failures identified in the Medicare-aged patient 
population with AF, coupled with the added 
outpatient costs associated with ablation failure, 
emphasizes the need for better understanding of 
prognostic factors for ablation outcome, since 
this would enable more targeted application.
In assessing the applicability of this economic 
analysis to clinical practice, several factors 
should be considered. The study was based on 
a limited patient sample drawn from specialist 
centers across the US over a 4-year period and, 
because of possible selection bias, caution is 
required in extrapolating these findings to the 
elderly AF ablation population in general. Latest 
figures indicate that the use of catheter ablation 
for treatment of AF in the Medicare population 
has risen markedly over the past decade, with 
the annual procedural volume increasing from 
315 cases in 2001 to 1975 cases in 2006.39 
Our exclusion of patients who showed no 
evidence of antiarrhythmic drug treatment in 
the 12 months immediately prior to ablation 
placed a possibly unnecessary constraint on 
study recruitment. It is possible that some of 
the elderly AF patients were referred for ablation 
several years after their original diagnosis, 
and that they may at some point have tried a 
rhythm-control strategy—but not within the 
12 months prior to ablation, and for this reason 
they were not included in the analysis. Due to 
its retrospective, nonrandomized design, we 
cannot rule out confounding factors (whether 
related to the patients, the disease, the ablation 
procedure, or standard of medical care) that 
may have influenced the clinical outcomes and 
cost differences seen in this study. Importantly, 
information was lacking regarding arrhythmia 
duration and persistence (paroxysmal, persistent, 
or chronic)—two of the most powerful 
predictors of AF ablation success—among the 
patients in this study. The procedural code 
used for identification of ablation procedures 
(CPT 93651) was not specific for AF ablation 
(there is no CPT code specifically for curative 
AF ablation procedures). The study may therefore 
have inadvertently captured AF patients 
undergoing ablation for other supraventricular 
tachycardias, although our exclusion of 
patients with ICD-9-CM diagnosis codes for 
paroxysmal supraventricular tachycardia and 
other supraventricular tachycardias makes this 
unlikely. Ablation success rate was determined 
indirectly, being defined in terms of freedom 
from antiarrhythmic drug therapy rather than 
freedom from arrhythmia recurrence, which 
can only be established by electrocardiogram 
monitoring. Given that elderly patients are 
likely to remain on antiarrhythmic drugs for 
precautionary reasons following AF ablation,26 
the study potentially underestimates the 
effectiveness of catheter ablation in restoring 
and maintaining sinus rhythm in this 
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population. Moreover, in the context of the 
current “hybrid” (ie, combined pharmacologic 
and nonpharmacologic) treatment approach 
to AF,40 continuation of antiarrhythmic drug 
therapy need not equate with ablation failure. 
It is conceivable that an ablation procedure, 
while failing to eradicate the electrophysiologic 
substrate for AF, might nevertheless facilitate 
subsequent pharmacologic cardioversion. At 
the same time, the study has the potential to 
overestimate AF ablation success rate, since the 
absence of antiarrhythmic therapy might instead 
be due to adoption of a rate-control approach. 
In addition, the rate of repeat ablation (5%) 
in this patient sample was considerably lower 
than that expected, suggesting possible patient 
selection bias. The study data were collected 
over a 12-month follow-up period, and the 
results should not be extrapolated beyond this 
time frame. Additionally, it should be borne 
in mind that the database was restricted to 
patients with Medicare supplemental insurance, 
who may not necessarily be representative 
of all Medicare beneficiaries with AF. Finally, 
the analysis took into account only the direct 
costs associated with AF ablation and the 
medical management of AF: no information 
was provided on complications associated with 
the ablation procedure or on AF-associated 
complications such as heart failure and stroke, 
and their likely impact on overall costs. With 
continuing growth in the use of catheter ablation 
for AF among the Medicare-aged population, 
the risk of clinical complications (particularly 
perforation, cardiac tamponade, and vascular 
access problems) can be expected to become 
an increasingly important consideration in 
this age-group.39 Despite these limitations, the 
study nevertheless provides useful insight into 
“real-world” practice among the Medicare-aged 
population until such time as the CABANA trial 
findings become available.
CONCLUSION
In the “real-world” (nonclinical-trial) 
setting, use of catheter ablation for second-line 
treatment of AF proved successful in ~50% of 
this limited sample of Medicare-aged patients. 
Overall, the annualized cost per patient of 
medical management of AF (ablation plus other 
AF-related services) was substantial, and tended 
to be higher in patients with failed ablation than 
in those with successful ablation ($19,997 vs. 
$16,049; P=0.07). This differential appeared to be 
due in part to the significantly higher pharmacy 
and outpatient costs incurred following ablation 
failure. However, in view of the small sample size 
and the inherent limitations of a claims-based 
analysis, caution is required in extrapolating 
these costs findings to the Medicare-aged 
AF ablation population as a whole.
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